rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LCTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Lineage Cell Therapeutics stock maintains Market Perform at Raymond James
      Nov 13Investing.comLINERJFLCTX
      What Lineage Cell Therapeutics (LCTX) Said on Its Q3 Earnings Call
      Nov 13Yahoo FinanceLINELCTX
      Lineage Cell Therapeutics earnings beat, revenue topped estimates
      Nov 13Investing.comLINELCTX
      Earnings call transcript: Lineage Cell rises on Q3 2026 pipeline update
      Nov 12Investing.comLINELCTX
      Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 12Yahoo FinanceLINELCTX
      Lineage Cell Therapeutics Inc (LCTX) (Q3 2026) Earnings Call Highlights: NeuroAermid ...
      Nov 12Yahoo FinanceLCTX
      Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
      Nov 5Yahoo FinanceLCTX
      Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call
      Oct 12BenzingaLINELCTX
      Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call - Lineage Cell Therapeutics (AMEX:

      On Thursday, Lineage Cell Therapeutics (AMEX:LCTX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For

      Oct 12BenzingaLCTX
      Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

      CARLSBAD, Calif., September 08, 2026--AlloSCOPE 5D Patent Release

      Sep 8Yahoo FinanceLINELCTX
      Lineage Cell Therapeutics: Balancing An Out-Licensed Pipeline Against Clinical Risk

      Lineage Cell Therapeutics is rated Hold due to its reliance on out-licensing and a risk-adjusted fair value below the current share price. Click for more.

      Sep 1Seeking AlphaLINELCTX

      This is the newest page. Registered accounts read further back.